ImmunityBio, Inc. - IBRX STOCK NEWS

ImmunityBio has initiated a Phase 2 clinical trial in Thailand for its interleukin-15 superagonist Anktiva® (N-803) in combination with antiretroviral therapy to combat HIV. Conducted by the U.S. Military HIV Research Program, the study aims to evaluate its effectiveness in inhibiting HIV reservoirs during acute infection. Preliminary Phase 1 data indicated Anktiva's safety and efficacy in activating immune responses. The 12-week study will assess immunostimulatory effects and viral load reduction.

ImmunityBio has treated over 100 patients with its proprietary Natural Killer (NK) cells in clinical trials targeting pancreatic, triple-negative breast, and Merkel Cell Carcinoma cancers. With over 5 trillion NK cells manufactured since 2017, the company has upgraded its production capabilities, resulting in a 400% performance increase. CEO Richard Adcock emphasized ImmunityBio's leading position in NK cell therapy manufacturing. The company also operates a broad immunotherapy pipeline with over 40 trials, including its lead agent Anktiva, which holds FDA breakthrough designations.

ImmunityBio (NASDAQ: IBRX) reported promising initial data from its Phase 1 study of a COVID-19 vaccine candidate, showing a significant ten-fold increase in T cell responses to spike and nucleocapsid proteins just 14-21 days post-vaccination. This data suggests the vaccine could provide broad protection, including against variants like B.1.1.7 and B.1.351. The innovative hAd5 vector vaccine may serve as a universal booster. ImmunityBio's ongoing Phase Ib trials aim to optimize vaccine administration methods for enhanced immunity against SARS-CoV-2.

ImmunityBio has appointed Dr. Linda Maxwell as an independent board member and CEO Richard Adcock to the board following the merger with NantKwest. Effective March 29, 2021, these appointments aim to enhance the company's leadership. Dr. Maxwell brings extensive healthcare and business experience, expected to guide ImmunityBio in developing innovative cancer therapies. Concurrently, board members Fred Driscoll and John D. Thomas concluded their service, having contributed to the company's significant pipeline expansion, which includes over 40 clinical trials.

ImmunityBio, Inc. (NASDAQ: IBRX) announced the publication of Phase I data in The Journal of ImmunoTherapy of Cancer. The study evaluated a second-generation hAd5 vaccine targeting multiple antigens in metastatic castration-resistant prostate cancer (mCRPC). Key findings include 100% of evaluated patients generating T-cell responses and a median overall survival probability of 83.3% at 12 months. The vaccine was safe, well-tolerated, and administered at a recommended dose without significant adverse events, indicating potential for future studies in cancer and infectious diseases.

ImmunityBio, Inc. (NASDAQ: IBRX) announced the publication of preclinical data in the Journal for ImmunoTherapy of Cancer, showcasing their PD-L1 t-haNK therapy's effectiveness in combination with T cell-based immunotherapy for treating heterogeneous tumors. The study suggests a sequential treatment approach using T cell immunotherapy followed by PD-L1 t-haNKs to enhance tumor control in relapsed solid cancers. Currently, ImmunityBio is conducting Phase 1/2 QUILT trials and has over 40 clinical trials underway across multiple cancer types.

ImmunityBio, Inc. (NASDAQ: IBRX) has announced the safety review results for its Phase Ib trials of a COVID-19 vaccine utilizing hAd5 technology. The independent Safety Review Committee recommended continuing the trials, which include 80 participants across sublingual and oral formulations. No serious adverse events were reported. Preliminary data from a BARDA-funded non-human primate study showed complete protection against the virus challenge. The trials aim to optimize administration routes for the vaccine, with enrollment expected to complete in Q2.

ImmunityBio, Inc. (NASDAQ: IBRX) announced the development of a novel hAd5 ACE2 Decoy therapeutic vaccine targeting SARS-CoV-2, including key mutations E484K and N501Y. Presented at the 28th CROI, the findings highlight the vaccine’s high binding affinity to these variants. The ACE2 Decoy aims to compete with natural ACE2 receptors in the respiratory tract to trap the virus and prevent infection. Given the rapid emergence of COVID-19 variants, this advancement is crucial for treatment and prevention efforts, warranting further clinical development.

ImmunityBio (NASDAQ: IBRX) has commenced trading as a large-cap company with approximately 398 million fully diluted shares following its merger with NantKwest. The combined entity is now listed on the Global Select Market of Nasdaq. ImmunityBio specializes in late-stage immunotherapy, focusing on innovative therapies for cancer and infectious diseases, backed by a pipeline of over 40 clinical trials in development across 19 indications. Its lead product, Anktiva™, has received favorable FDA designations for certain bladder cancer treatments.